Electrospun cationic nanofibers and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-10066323-B2
Application number	US-201515304416-A
Country	US
Kind code	B2
Filing date	Apr 16, 2015
Priority date	Apr 16, 2014
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

Methods of making polycationic nanofibers by grafting cationic polymers onto electrospun neutral nanofibers and polycationic nanofibers produced by the methods are provided herein. In addition, methods of using the polycationic nanofibers to reduce inflammation, to adsorb anionic compounds such as heparin or nucleic acids, to inhibit the growth of microbes or inhibit the formation of a biofilm are also provided. The polycationic nanofibers may be in a mesh and may be included in a medical device, wound dressing, bandage, or as part of a graft.

First claim

We claim:

1. A method of using a polycationic nanofiber comprising applying the polycationic nanofiber to cells or a tissue at a site of inflammation or infection having a biofilm or microbes capable of forming a biofilm associated therewith in vivo, wherein the polycationic nanofiber reduces the inflammation or infection at the site,
wherein the neutral polymer is poly-styrene maleic anhydride, wherein the polycationic nanofiber comprises a neutral polymer nanofiber less than 2 μm in diameter and a second polymer grafted thereon,
wherein the second polymer is selected from the group consisting of branched polyethyleneimine (bPEI) and polyamindoamine (PAMAM);
wherein the biofilm comprises bacteria selected from the group consisting of Bacillus spp., Corynebacterium spp., Listeria spp., Staphylococcus spp., Micrococcus spp., lactic acid bacteria Lactobacillus spp., Lactococcus spp., Entercoccus spp., Streptococcus spp., Escherichia spp., Klebsiella spp., Pseudomonas spp., Proteus spp., Legionella spp., Rhizobium spp., Sinorhizobium spp., and Serratia spp.; and
wherein cellular viability of the cells or the tissue after application of the polycationic nanofiber is reduced by less than 50% as compared to untreated control cells.

2. A method of using a polycationic nanofiber comprising contacting the polycationic nanofibers with cells or a tissue and a solution comprising an anion in vivo, wherein the anion is adsorbed onto the polycationic nanofibers,
wherein the neutral polymer is poly-styrene maleic anhydride, wherein the polycationic nanofiber comprises a neutral polymer nanofiber less than 2 μm in diameter and a second polymer grafted thereon,
wherein the second polymer is selected from the group consisting of branched polyethyleneimine (bPEI) and polyamindoamine (PAMAM);
wherein the solution comprising the anion comprises a biofilm or microbes capable of forming a biofilm at a site of infection;
wherein the biofilm comprises bacteria selected from the group consisting of Bacillus spp., Corynebacterium spp., Listeria spp., Staphylococcus spp., Micrococcus spp., lactic acid bacteria Lactobacillus spp., Lactococcus spp., Entercoccus spp., Streptococcus spp., Escherichia spp., Klebsiella spp., Pseudomonas spp., Proteus spp., Legionella spp., Rhizobium spp., Sinorhizobium spp., and Serratia spp.; and
wherein cellular viability of the cells or the tissue after application of the polycationic nanofiber is reduced by less than 50% as compared to untreated control cells.

3. The method of claim 2 , wherein the polycationic nanofibers are added in an amount effective to inhibit formation of the biofilm or prevent infectious wound formation.

4. The method of claim 2 , wherein the anion is selected from a nucleic acid, heparin, or enoxaparin.

5. The method of claim 4 , wherein the nucleic acid comprises dsRNA, ssRNA, un- or hypo-methylated DNA, or ssDNA.

6. The method of claim 2 , wherein the polycationic nanofibers are incorporated into a medical device, bandage, dressing, graft, mesh, or wound dressing.

7. The method of claim 1 , wherein the second polymer comprises a generation 0-4 PAMAM.

8. The method of claim 1 , wherein the nanofiber is prepared by electro spinning the neutral polymer to produce the neutral polymer nanofiber and grafting the second polymer on the neutral polymer nanofiber.

9. The method of claim 1 , wherein the polycationic nanofibers are incorporated into a medical device, bandage, dressing, graft, mesh, or wound dressing.

10. The method of claim 2 , wherein the second polymer comprises a generation 0-4 PAMAM.

11. The method of claim 2 , wherein the nanofiber is prepared by electro spinning the neutral polymer to produce the neutral polymer nanofiber and grafting the second polymer on the neutral polymer nanofiber.

12. The method of claim 1 , wherein the polycationic nanofibers are added in an amount effective to inhibit formation of the biofilm or prevent infectious wound formation.

Assignees

• Univ Duke

Inventors

• Sullenger Bruce A
• Juwarker Hemraj A
• Leong Kam W
• Gamboa Jackman Jennifer

Classifications

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• D10B2509/022

  Wound dressings · CPC title

• A61L15/44

  Medicaments · CPC title

• D01F6/42

  comprising cyclic compounds containing one carbon-to-carbon double bond in the side chain as major constituent · CPC title

• D06M15/00

  Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment (D06M10/00, D06M14/00 take precedence; {treatment with inorganic polyphosphates D06M11/72}) · CPC title